Search

Displaying results 6621 - 6630 of 9322 in total
  1. Drug

    Surzetoclax

    go.drugbank.com/drugs/DB21698
    Investigational

    The usage of the INN stem '-toclax' in the name indicates that Surzetoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Surzetoclax has a monoisotopic molecular weight of 1038.41 Da.

  2. Drug

    1alpha,24S-Dihydroxyvitamin D2

    go.drugbank.com/drugs/DB06117
    Experimental

    LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol. … It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.

  3. Drug

    OAV201

    go.drugbank.com/drugs/DB17842
    Experimental

    OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter … It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical trials was halted.[L46661]

  4. Drug

    Linopristin

    go.drugbank.com/drugs/DB19296
    Experimental

    Linopristin is an antibiotic of the streptogramin B class. It is one part of the combination product NXL 103, along with [Virginiamycin M1]. … The combination product was under investigation in clinical trials NCT00653172 and NCT00949130 for treatment of various bacterial infections.

  5. Drug

    Azilsartan mopivabil

    go.drugbank.com/drugs/DB21569
    Experimental

    The usage of the INN stem '-sartan' in the name indicates that Azilsartan mopivabil is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

  6. Drug

    Riselcaftor

    go.drugbank.com/drugs/DB21685
    Experimental

    The usage of the INN stem '-caftor' in the name indicates that Riselcaftor is a Cystic fibrosis transmembrane regulator (CFTR) protein modulator, corrector, and amplifier.

  7. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

  8. Drug

    R1204

    go.drugbank.com/drugs/DB05118
    Experimental

    It is developed for the treatment of depression.

  9. Drug

    Evifacotrep

    go.drugbank.com/drugs/DB21510
    Investigational

    The usage of the INN stem '-cotrep' in the name indicates that Evifacotrep is a transient receptor potential canonical channel 5 (TRPC5) antagonist.

  10. Drug

    Carafiban

    go.drugbank.com/drugs/DB19813
    Experimental

    The usage of the INN stem '-fiban' in the name indicates that Carafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).